HK Stock Market Move | CSTONE PHARMA-B (02616) is rising by over 4% again. Its core commercial product, sugerlimab, has received an ESMO guideline recommendation of Grade I, A.

CSTONE PHARMA-B (02616) rose more than 4%, as of the time of writing, up 3.77% to HKD 7.14, with a turnover of HKD 35.6465 million. On the news front, on March 25th, CSTONE PHARMA-B announced that its core commercial product, sugemalimab, received a Grade I, A recommendation from the European Society for Medical Oncology (ESMO). Sugemalimab has been included in the "Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline" for use in the consolidation treatment of Stage III non-small-cell lung cancer (NSCLC) patients after synchronous or sequential chemotherapy. This recommendation will significantly support the market access process of sugemalimab in the EU and other markets, benefiting a wider range of patients and providing solid support for its global commercial expansion. In February 2025, the combination of sugemalimab and chemotherapy received a Grade I, A recommendation from ESMO for the first-line treatment of squamous and non-squamous Stage IV NSCLC with no driver gene mutations. Thus, sugemalimab has now been included in the ESMO guidelines for two lung cancer indications approved in the EU and UK, demonstrating its clinical value. As of now, sugemalimab has established four commercial partnerships in Europe, the Middle East and Africa, and Latin America, with a commercial network spanning over sixty countries and regions globally. Market access applications have been approved or are under review in more than ten countries, and overseas commercial deployment is steadily and efficiently advancing.